These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 23586508)

  • 1. Three-year follow-up of lanthanum carbonate therapy in hemodialysis patients.
    Takeuchi K; Matsuda E; Sekino M; Hasegawa Y; Kamo Y; Kikuchi N; Sekino H
    Ther Apher Dial; 2013 Apr; 17 Suppl 1():15-21. PubMed ID: 23586508
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Study of prolonged administration of lanthanum carbonate in dialysis patients.
    Gotoh J; Kukita K; Tsuchihashi S; Hattori M; Iida J; Horie T; Onodera K; Furui H; Tamaki T; Meguro J; Yonekawa M; Kawamura A
    Ther Apher Dial; 2013 Apr; 17 Suppl 1():9-14. PubMed ID: 23586507
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical effects of long-term (36-month) lanthanum carbonate administration in hemodialysis patients in Japan.
    Kishi Y; Obara Y; Hara K; Yamashiro H; Kurosawa N; Takada D
    Ther Apher Dial; 2014 Jun; 18 Suppl 1():9-13. PubMed ID: 24953760
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improvement of MBD parameters in dialysis patients by a switch to, and combined use of lanthanum carbonate: Josai Dialysis Forum collaborative study.
    Shinoda T; Yamasaki M; Chida Y; Takagi M; Tanaka Y; Ando R; Suzuki T; Tagawa H
    Ther Apher Dial; 2013 Apr; 17 Suppl 1():29-34. PubMed ID: 23586510
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of continuous oral administration of lanthanum carbonate over 24 months.
    Ishizu T; Hong Z; Matsunaga T; Kaneko Y; Taru Y
    Ther Apher Dial; 2013 Apr; 17 Suppl 1():22-8. PubMed ID: 23586509
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of lanthanum carbonate in the treatment of hyperphosphatemia in dialysis patients: a Canadian payer perspective.
    Vegter S; Tolley K; Keith MS; Lok CE; Soroka SD; Morton AR
    Clin Ther; 2012 Jul; 34(7):1531-43. PubMed ID: 22742885
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The real-world dose-relativity of sevelamer hydrochloride and lanthanum carbonate monotherapy in patients with end-stage renal disease.
    Wilson RJ; Keith MS; Preston P; Copley JB
    Adv Ther; 2013 Dec; 30(12):1100-10. PubMed ID: 24307220
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparative study of phosphate binders in patients with end stage kidney disease undergoing hemodialysis.
    Prajapati VA; Galani VJ; Shah PR
    Saudi J Kidney Dis Transpl; 2014 May; 25(3):530-8. PubMed ID: 24821148
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multicenter prospective randomized, double-blind comparative study between lanthanum carbonate and calcium carbonate as phosphate binders in Japanese hemodialysis patients with hyperphosphatemia.
    Shigematsu T;
    Clin Nephrol; 2008 Nov; 70(5):404-10. PubMed ID: 19000540
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of switching from calcium carbonate to lanthanum carbonate on bone mineral metabolism in hemodialysis patients.
    Manabe R; Fukami K; Ando R; Sakai K; Kusumoto T; Hazama T; Adachi T; Kaida Y; Nakayama Y; Ueda S; Kohno K; Wada Y; Yamagishi S; Okuda S
    Ther Apher Dial; 2013 Apr; 17 Suppl 1():35-40. PubMed ID: 23586511
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lanthanum carbonate vs. sevelamer hydrochloride for the reduction of serum phosphorus in hemodialysis patients: a crossover study.
    Sprague SM; Ross EA; Nath SD; Zhang P; Pratt RD; Krause R
    Clin Nephrol; 2009 Oct; 72(4):252-8. PubMed ID: 19825330
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized crossover study of the efficacy and safety of sevelamer hydrochloride and lanthanum carbonate in Japanese patients undergoing hemodialysis.
    Kasai S; Sato K; Murata Y; Kinoshita Y
    Ther Apher Dial; 2012 Aug; 16(4):341-9. PubMed ID: 22817122
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lanthanum carbonate provides control of phosphorus levels in patients new to phosphate binder therapy and patients changed from other phosphate binders.
    Noto L
    J Ren Nutr; 2011 May; 21(3):277-82. PubMed ID: 20598905
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of lanthanum carbonate vs. calcium carbonate on serum calcium in hemodialysis patients: a crossover study.
    Toida T; Fukudome K; Fujimoto S; Yamada K; Sato Y; Chiyotanda S; Kitamura K
    Clin Nephrol; 2012 Sep; 78(3):216-23. PubMed ID: 22874110
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-minimization analysis of lanthanum carbonate versus sevelamer hydrochloride in US patients with end-stage renal disease.
    Keith MS; Wilson RJ; Preston P; Copley JB
    Clin Ther; 2014 Sep; 36(9):1276-86. PubMed ID: 25069799
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multicenter study on the long-term (3-year) efficacy of lanthanum carbonate in dialysis patients.
    Ando R; Yama S; Ohnishi T; Iwamoto S; Kimura H; Chida Y; Ishida Y; Yamada K; Inagaki Y; Takayama M; Tachibana K; Kikuchi K; Inoue A; Ohtsuka M
    Ther Apher Dial; 2014 Jun; 18 Suppl 1():2-8. PubMed ID: 24953759
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multicenter study of long-term (two-year) efficacy of lanthanum carbonate.
    Ando R; Kimura H; Sato H; Iwamoto S; Yoshizaki Y; Chida Y; Ishida Y; Takayama M; Yamada K; Tachibana K; Ohtsuka M; Kikuchi K; Inoue A
    Ther Apher Dial; 2013 Apr; 17 Suppl 1():2-8. PubMed ID: 23586506
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A multicenter study on the effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease in dialysis patients.
    D'Haese PC; Spasovski GB; Sikole A; Hutchison A; Freemont TJ; Sulkova S; Swanepoel C; Pejanovic S; Djukanovic L; Balducci A; Coen G; Sulowicz W; Ferreira A; Torres A; Curic S; Popovic M; Dimkovic N; De Broe ME
    Kidney Int Suppl; 2003 Jun; (85):S73-8. PubMed ID: 12753271
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-world dose-relativity, tablet burden, and cost comparison of conversion between sevelamer hydrochloride/carbonate and lanthanum carbonate monotherapies.
    Keith MS; Sibbel S; Copley JB; Wilson RJ; Brunelli SM
    Clin Ther; 2014 Oct; 36(10):1431-42.e1. PubMed ID: 25150194
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of sevelamer hydrochloride with colestimide, administered alone or in combination with calcium carbonate, in patients on hemodialysis.
    Itoh K; Tanaka M; Hashiguchi J; Funakoshi S; Nakano H; Kubo H; Kono T; Uchino J; Masaki K; Date T; Shigematsu T;
    Ther Apher Dial; 2008 Apr; 12(2):126-32. PubMed ID: 18387160
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.